Company intelligence / Profile preview
Abliva AB
Lund, Swedenabliva.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Abliva (formerly NeuroVive) is focused on developing treatments for primary mitochondrial diseases. The company has one project in clinical phase I (KL1333) for chronic treatment of genetic mitochondrial diseases and has completed early Phase 2 studies for NeuroSTAT for traumatic brain injury.
- Therapeutic areas
- GastroenterologyRare DiseasesNeurologyCardiovascular
- Modalities
- Small moleculesCyclosporine-based compounds
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Yungjin Pharm CorpSihuan Pharmaceuticalto-BBBSelcia Limited
Beyond the preview
Go deeper on Abliva AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abliva AB.